NYSEAMERICAN:AST Asterias Biotherapeutics (AST) Stock Price, News & Analysis $0.0020 0.00 (0.00%) (As of 07/10/2019) Add Compare Share Share Today's Range$0.0020▼$0.002050-Day Range N/A52-Week Range$0.51▼$2.05Volume1,000 shsAverage Volume136,653 shsMarket Capitalization$111,318.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Asterias Biotherapeutics alerts: Email Address Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About Asterias Biotherapeutics Stock (NYSEAMERICAN:AST)Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.Read More AST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AST Stock News HeadlinesAugust 13, 2024 | seekingalpha.comARTV Artiva Biotherapeutics, Inc.July 19, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Names Russell L. Skibsted as Chief Financial OfficerSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.May 20, 2024 | businesswire.comApplications Software Technology Acquires Symatrix to Accelerate Global Expansion in Oracle Cloud ServicesApril 30, 2024 | uk.finance.yahoo.comBritish & American Investment Trust Plc - Annual Financial ReportMarch 27, 2024 | seekingalpha.comCLDI Calidi Biotherapeutics, Inc.February 17, 2024 | morningstar.comProtalix BioTherapeutics Inc PLXNovember 27, 2023 | benzinga.comCalidi Biotherapeutics Stock (AMEX:CLDI) Dividends: History, Yield and DatesSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.November 22, 2023 | morningstar.comBarinthus Biotherapeutics PLC ADRNovember 2, 2023 | morningstar.comCalidi Biotherapeutics Inc Ordinary Shares - Class AJuly 18, 2023 | benzinga.comArcutis Biotherapeutics Stock (NASDAQ:ARQT), Analyst Ratings, Price Targets, PredictionsMay 21, 2023 | fool.comIovance Biotherapeutics (NASDAQ: IOVA)May 11, 2023 | marketwatch.comHuman Embryonic Stem Cells (HESC) Market Future Investments and Forecast Till 2030May 8, 2023 | investing.comBrightPath Biotherapeutics Co Ltd (4594)March 14, 2023 | marketwatch.comHuman Embryonic Stem Cells (HESC) Market: Analyzing Growth Opportunities and Industry Trends for 2023-2028March 9, 2023 | marketwatch.com2023-2029 Human Embryonic Stem Cells (HESC) Market Size and Regional Analysis | Research Report by Absolute ReportsMarch 7, 2023 | marketwatch.comStem Cell Therapy for Osteoarthritis Market Expert Industrial Investigation Report 2023-2028See More Headlines Receive AST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Asterias Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2017Today9/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:AST Previous SymbolNYSEMKT:AST CUSIPN/A CIKN/A Webasteriasbiotherapeutics.com Phone+1-510-4563805FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares55,659,000Free FloatN/AMarket Cap$111,318.00 OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Michael H. Mulroy (Age 53)CEO, Pres & Director Dr. Edward D. Wirth III (Age 54)Chief Medical Officer Dr. Katharine E. Spink (Age 45)Consultant Mr. Stephen L. Cartt (Age 56)Advisor & Director Mr. Ryan D. Chavez (Age 43)CFO & Gen. Counsel Key CompetitorsDiadexusOTCMKTS:DDXSRespireRx PharmaceuticalsOTCMKTS:RSPIDKaleido BiosciencesNASDAQ:KLDO180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBFView All Competitors AST Stock Analysis - Frequently Asked Questions How were Asterias Biotherapeutics' earnings last quarter? Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) issued its quarterly earnings data on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to analyst estimates of $2.81 million. How do I buy shares of Asterias Biotherapeutics? Shares of AST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Asterias Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Asterias Biotherapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Sangamo Therapeutics (SGMO) and This page (NYSEAMERICAN:AST) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Asterias Biotherapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Asterias Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.